These are important issues because the potential finding that embryonic or chronic expression of Gαi2G184S is required for cardioprotection would likely preclude the use of pharmacological RGS inhibitors from therapeutic use in the treatment of ischemic heart disease. Here, PITX2 is linked to coronary artery disorder.